EGFR-IN-134

EGFR-IN-134 is a potent triazoloquinoline-based EGFR inhibitor (IC50: 0.023 μM) that exhibits anticancer activity by inducing apoptosis, necrosis, and G2/M cell cycle arrest. It modulates key apoptotic proteins, including downregulating Bcl-2 and upregulating p53, Bax, and caspases. This compound is a valuable tool for in vitro cancer research, particularly in studying EGFR-driven proliferation and cell death mechanisms.